Analyst Downgrades: Tetraphase, Flexion, and MannKind

Analysts downwardly revised their ratings and price targets on Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), Flexion Therapeutics Inc (NASDAQ:FLXN), and MannKind Corporation (NASDAQ:MNKD)

Sep 9, 2015 at 10:03 AM
facebook X logo linkedin

Analysts are weighing in on drugmakers Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)Flexion Therapeutics Inc (NASDAQ:FLXN), and MannKind Corporation (NASDAQ:MNKD). Here's a quick roundup of today's bearish brokerage notes on TTPH, FLXN, and MNKD.

  • Unlike another of its drugmaker peersTTPH is having a disastrous morning. The shares have plummeted 79% to $9.40 -- and panned an annual low of $9 -- after the company announced its experimental bowel drug failed in a late-stage study. The bearish brokerage notes have since poured in, with Nomura, for one, cutting the stock's rating to "neutral" from "buy," while slashing its price target to $10 from $54. Before today, Tetraphase Pharmaceuticals Inc had easily doubled on the charts during the past 12 months -- helping to explain why 100% of covering analysts considered the shares worthy of a "buy" or better endorsement -- but now finds itself in territory not seen since May 2014. 

  • FLXN is suffering a similar fate this morning, with the shares sliding 30.4% after the company revealed its experimental pain drug failed in a mid-stage study. Short sellers are likely pleased with this news, however; specifically, short interest shot 42.2% higher during the most recent two-week reporting period. Now, it would take these bears almost seven days to repurchase their shares, at Flexion Therapeutics Inc's average daily trading pace. With FLEX trading at $20.18, it's now sitting 46.3% below its consensus 12-month price target of $37.60. Needham, though, just trimmed its price target on the equity to $28 from $31.

  • Finally, MNKD is down 7.5% at $3.77, following a downgrade to "underweight" from "neutral," and a price-target cut to $1.50 from $4, at Piper Jaffray. In its note, the brokerage firm stated MannKind Corporation has "vastly over-estimated" the potential of its diabetes drug Afrezza. Despite historically outperforming in September, the stock has barely budged on a month-to-date basis. Longer term, MNKD has underperformed the S&P 500 Index (SPX) by 29.4 percentage points during the past 60 sessions. As such, short sellers have been piling on, with 45.6% of the stock's float sold short -- or 21.6 times the average daily trading level.
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI